These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 22025647

  • 1. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 3. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
    Jin HY, Liu WJ, Park JH, Baek HS, Park TS.
    Arch Med Res; 2009 Oct 17; 40(7):536-44. PubMed ID: 20082866
    [Abstract] [Full Text] [Related]

  • 4. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S.
    Biochem Pharmacol; 2012 Jan 15; 83(2):241-52. PubMed ID: 22015634
    [Abstract] [Full Text] [Related]

  • 5. Abelmoschus esculentus subfractions improved nephropathy with regulating dipeptidyl peptidase-4 and type 1 glucagon-like peptide receptor in type 2 diabetic rats.
    Peng CH, Lin HC, Lin CL, Wang CJ, Huang CN.
    J Food Drug Anal; 2019 Jan 15; 27(1):135-144. PubMed ID: 30648566
    [Abstract] [Full Text] [Related]

  • 6. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
    Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, Dokkum RP, Buikema H.
    Curr Vasc Pharmacol; 2014 Jan 15; 12(6):836-44. PubMed ID: 24066937
    [Abstract] [Full Text] [Related]

  • 7. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.
    Vallon V, Docherty NG.
    Exp Physiol; 2014 Sep 15; 99(9):1140-5. PubMed ID: 25085841
    [Abstract] [Full Text] [Related]

  • 8. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):297-306. PubMed ID: 22820107
    [Abstract] [Full Text] [Related]

  • 9. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S, Sole S.
    Eur J Pharm Sci; 2012 Sep 29; 47(2):456-63. PubMed ID: 22800967
    [Abstract] [Full Text] [Related]

  • 10. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, Silva ME, de Lima WG, Costa DC.
    Arch Med Res; 2013 Apr 29; 44(3):194-202. PubMed ID: 23523961
    [Abstract] [Full Text] [Related]

  • 11. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M.
    Pharmacol Rep; 2009 Apr 29; 61(5):899-908. PubMed ID: 19904014
    [Abstract] [Full Text] [Related]

  • 12. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.
    Jin L, Lim SW, Doh KC, Piao SG, Jin J, Heo SB, Chung BH, Yang CW.
    PLoS One; 2014 Apr 29; 9(6):e100798. PubMed ID: 24959755
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Physiology and pathophysiology of incretins in the kidney.
    von Websky K, Reichetzeder C, Hocher B.
    Curr Opin Nephrol Hypertens; 2014 Jan 29; 23(1):54-60. PubMed ID: 24257158
    [Abstract] [Full Text] [Related]

  • 17. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S.
    Eur J Pharmacol; 2016 Jul 15; 783():56-63. PubMed ID: 27063445
    [Abstract] [Full Text] [Related]

  • 18. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S, Fujita H, Fujishima H, Shimizu T, Sato T, Morii T, Tsukiyama K, Narita T, Takahashi T, Drucker DJ, Seino Y, Yamada Y.
    Kidney Int; 2016 Oct 15; 90(4):783-96. PubMed ID: 27475229
    [Abstract] [Full Text] [Related]

  • 19. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.
    Gastroenterology; 2009 Dec 15; 137(6):2146-57. PubMed ID: 19766644
    [Abstract] [Full Text] [Related]

  • 20. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
    Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM.
    Cardiovasc Diabetol; 2013 Oct 22; 12():154. PubMed ID: 24148218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.